The Effect of Valproate on the Required Dose of Propofol for Sedation in Patients With Mental Retardatio
Not Applicable
- Conditions
- Patients with oral valproate
- Registration Number
- JPRN-UMIN000006228
- Lead Sponsor
- Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Siences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Patients can communicate and cooperate with dental treatment. Patients need premedication and inhalational anesthetics. ASA physical status is 3 or 4. The complications are not controlled by oral drugs. There is a tendency of somnolence before treatment due to the influence of medicine. Patients have oral antiepileptic or psyhotropic drug medication excluding valproate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The required dose of propofol
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does valproate modulate GABAergic pathways to reduce propofol sedation requirements in mental retardation patients?
What comparative effectiveness data exist for valproate versus standard anticonvulsants in adjusting propofol dosing for sedation in intellectual disability?
Which genetic biomarkers correlate with valproate-induced changes in propofol pharmacodynamics in patients with neurodevelopmental disorders?
What adverse event profiles are associated with valproate-propofol combination sedation in mental retardation populations?
How do HDAC inhibitors like valproate interact with propofol's anesthetic mechanisms in neurologically impaired patients?